20
Participants
Start Date
September 7, 2023
Primary Completion Date
March 24, 2025
Study Completion Date
July 10, 2025
Bomedemstat
Oral tablet
Monash Medical Centre ( Site 0006), Clayton
Sunshine Coast Hematology and Oncology Clinic (Site 0506), Sunshine Coast
Royal Perth Hospital ( Site 0504), Perth
Duke University Medical Center ( Site 0016), Durham
BRCR Global ( Site 0120), Plantation
Ohio State University Comprehensive Cancer Center ( Site 0103), Columbus
University of Michigan Comprehensive Cancer Center ( Site 0008), Ann Arbor
Huntsman Cancer Hospital at the University of Utah ( Site 0119), Salt Lake City
Comprehensive Cancer Centers of Nevada - Peak ( Site 0118), Las Vegas
Hematology Oncology of the North Shore ( Site 0104), Skokie
OHSU Knight Cardiovascular Institute Cardiology Clinic - South Waterfront ( Site 0102), Portland
Gloucestershire Royal Hospital ( Site 0205), Gloucester
United Lincolnshire Hospitals NHS Trust ( Site 0204), Lincoln
Imperial College London ( Site 0025), London
Boston Pilgrim Hospital ( Site 0207), Boston
Guys and St Thomas NHS Foundation Trust - Guys Hospital ( Site 0020), London
Royal Gwent Hospital ( Site 0201), Newport
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
INDUSTRY